Amphastar Pharmaceuticals, Inc. (FRA:29A)

Market Cap	1.02B -39.5%
Revenue (ttm)	616.47M -0.0%
Net Income	95.14M -29.2%
EPS	1.93 -24.6%
Shares Out	n/a
PE Ratio	10.77
Forward PE	7.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	21.33
Previous Close	21.74
Day's Range	21.33 - 21.33
52-Week Range	17.24 - 35.06
Beta	n/a
RSI	41.46
Earnings Date	Feb 27, 2026

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emer...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 2,028
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 29A

Financial Performance

In 2024, Amphastar Pharmaceuticals's revenue was $731.97 million, an increase of 13.59% compared to the previous year's $644.40 million. Earnings were $159.52 million, an increase of 15.98%.

Financial numbers in USD